# Eric Gornstein

> Eric Gornstein is the Chief Executive Officer of Pearl Diagnostics, a Johns Hopkins spinout in Baltimore that makes MycoMEIA, the first FDA-cleared urine test for invasive aspergillosis. A biopharma commercialization veteran with more than 25 years leading product launches, partnering and deal-making across therapeutic areas, he joined Pearl in late 2025 to take the company from FDA clearance to the market and into Europe. Earlier he helped launch Radius Health's first product, Tymlos, and worked in business development and cell therapy partnerships at companies including bit.bio and Talaris Therapeutics.

- **Role:** Chief Executive Officer at Pearl Diagnostics, Inc.
- **Organizations:** Pearl Diagnostics, Inc., bit.bio, Talaris Therapeutics, Radius Health, Inc.
- **Nationality:** American
- **Education:** Executive MBA, Massachusetts Institute of Technology - Sloan School of Management
- **Known for:** Appointed CEO of Pearl Diagnostics, a Johns Hopkins spinout, to lead go-to-market for MycoMEIA, the first FDA-cleared non-invasive urine assay for invasive aspergillosis., Helped build the commercial operations infrastructure and led insights and analytics for the US launch of Radius Health's Tymlos., Structured, negotiated and executed buy- and sell-side biopharma deals with top global companies across multiple therapeutic areas and modalities.

## Career timeline

- **Radius Health** — Led commercial insights and analytics and helped build the commercial operations organization to launch the company's first product, Tymlos, in the United States.
- **Talaris Therapeutics** — Held a business development and strategy leadership role in cell therapy.
- **bit.bio** — Served as Senior Vice President, Business Development and Cell Therapy Partnerships.
- **2025** — Joined Pearl Diagnostics in the fall to lead commercialization; appointed Chief Executive Officer.
- **2026** — Pearl Diagnostics closed an $11.2M Series A to market MycoMEIA in the US and expand into Europe.

## Achievements

- Appointed CEO of Pearl Diagnostics, a Johns Hopkins spinout, to lead go-to-market for MycoMEIA, the first FDA-cleared non-invasive urine assay for invasive aspergillosis.
- Helped build the commercial operations infrastructure and led insights and analytics for the US launch of Radius Health's Tymlos.
- Structured, negotiated and executed buy- and sell-side biopharma deals with top global companies across multiple therapeutic areas and modalities.
- Guided Pearl Diagnostics through an $11.2M Series A raise in 2026 to fund US commercialization and European expansion.

## Latest updates

- **2026-03** — Pearl Diagnostics announced an $11.2M Series A round to fund US marketing and European expansion of MycoMEIA.
- **2025-11** — Eric Gornstein featured as CEO on the Pearl Diagnostics leadership page.
- **2025-08** — Pearl Diagnostics received FDA 510(k) clearance for the MycoMEIA Aspergillus urine assay.

## Links

- Website: https://pearldx.com
- LinkedIn: http://www.linkedin.com/in/eric-gornstein

---

Profile page: https://yespress.io/eric-gornstein
Published by YesPress — https://yespress.io
Last updated: 2026-07-17